Cancer: Principles & Practice of Oncology

by Vincent T. DeVita Jr., Steven A. Rosenberg, Theodore S. Lawrence (Editor)

Acclaimed by the worldwide medical community as "a staple reference text in the medical oncologist's library" (JAMA), DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology is now in its Eighth Edition. This edition is in full color for the first time, has a new editor, Theodore S. Lawrence, MD, PhD, a radiation oncologist, and has two Associate Scientific Advisors, Ronald A. DePinho, MD and Robert A. Weinberg, PhD, with special expertise in molecular biology. More than 40 chapters are entirely new, and more than 70 have been rewritten by new contributing authors. Plus, this edition has an exciting new companion Website.

The text provides cutting-edge, practical information on the science of oncology and the multimodality treatment of every cancer type. To ensure a balanced, multidisciplinary approach, each major treatment chapter is co-authored by a surgeon, a medical oncologist, and a radiation oncologist. Treatment of each cancer type is discussed by stage, with coordinated guidelines on the role of each treatment modality at each stage. Each major treatment section is preceded by an updated brief chapter describing the molecular biology of the cancer and the implications of molecular biology for patient management. Full consideration is also given to cancer prevention, screening, palliative care, supportive oncology, and quality of life issues.

A companion Website offers the fully searchable online text, an image bank, links to journal articles, and a question bank.

2448 pages, Hardcover

First published January 28, 1982

About the author

An internationally recognized pioneer physician in the field of oncology.

DeVita earned his Bachelor of Science degree from the College of William and Mary in 1957. He was awarded his MD degree with distinction from the George Washington University School of Medicine in 1961.
DeVita spent the early part of his career at the National Cancer Institute (NCI). In 1980, the president of the United States appointed him as director of the NCI and the National Cancer Program, a position he held until 1988. While at the NCI, he was instrumental in developing combination chemotherapy programs that ultimately led to an effective regimen of curative chemotherapy for Hodgkin's disease and diffuse large cell lymphomas. Along with colleagues at the NCI, he developed the four-drug combination, known by the acronym MOPP, which increased the cure rate for patients with advanced Hodgkin's disease from nearly zero to over 70%.